GeneNews platform identifies blood biomarkers for NPC

In a presentation at the 2011 Asia Pacific Cancer Conference, GeneNews (TSX:GEN) reported that a study using its proprietary Sentinel Principle platform technology identified blood-based biomarkers that distinguished nasopharyngeal carcinoma (NPC) patients from controls and from patients with other cancers with high accuracy. NPC is a common cancer in certain parts of Northern Africa and [...]

GeneNews launches ColonSentry in Malaysia

GeneNews (TSX:GEN) has announced the commercial launch of ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer, in Malaysia through its GeneNews Diagnostics Sdn. Bhd. subsidiary. “We are excited that GeneNews Diagnostics will now be able to provide the Malaysian population with access to this potentially life-saving colorectal cancer [...]

GeneNews holders okay stock consolidation

Shareholders of GeneNews (TSX:GEN) at a special meeting approved a proposed share consolidation of the basis of one post-consolidation common share for every six pre-consolidation common shares. The timing for implementation of the consolidation will be determined by the company’s board of directors, but will be no later than Jan. 31, 2012. “We believe that [...]

GeneNews launches SentinelGx

GeneNews (TSX: GEN) has launched SentinelGx, a suite of pharmacogenomic and companion diagnostic BloodRNA services for drug development and personalized health management applications. SentinelGx services provide complete whole blood transcriptome analysis for RNA expression profiling of inflammatory pathways, immune system response and cell signalling based on the company’s patented Sentinel Principle technology. A catalog of [...]

GeneNews raises $2.1 Million

GeneNews (TSX: GEN) has accepted subscription agreements with a number of investors for two concurrent private placement offerings of units and convertible debentures to raise gross proceeds of $2,125,452, with insiders subscribing for about 49%. Each unit consists of one common share, one-half of a Series A warrant and one-half of a Series B warrant. [...]

GeneNews completes deal to bring ColonSentry to China

GeneNews (TSX:GEN) has executed a formal marketing partnership agreement with GeneDiagnostics, a private clinical research and services company in China, to market ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer. Under the accord, GeneDiagnostics has obtained non-exclusive rights to market and sell the ColonSentry test in Shanghai and [...]

Malaysian study further validates GeneNews’ ColonSentry

A 210-patient Malaysian study entitled “Blood-based Seven-gene Biomarker Panel for Colorectal Cancer: Validation in Malaysia” has been presented at the 2010 National Committee for Clinical Research conference in Kuala Lumpur. GeneNews (TSX:GEN) said the seven-gene biomarker panel forms the basis of its lead ColonSentry product, the world’s first blood test for colorectal cancer.  The abstract [...]

GeneNews partners to sell ColonSentry in China

GeneNews (TSX:GEN) signed a binding term sheet with GeneDiagnostics, a private clinical research and services company in China, for the non-exclusive rights to market ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer. GeneNews expects negotiations will lead to a formal marketing partnership agreement by the end of June. [...]

U.S. grants another two patents to GeneNews on Sentinel Principle

GeneNews (TSX:GEN) was granted two new U.S. patents on its core Sentinel Principle platform technology, covering “Biomarkers for Diagnosing Schizophrenia” and “Mild Osteoarthritis Biomarkers and Uses Thereof.” The schizophrenia patent covers any analysis of a blood sample in which the expression pattern of a 9-gene panel is assessed in a diagnosis of schizophrenia.  The mild [...]

GeneNews names Auld as CFO

GeneNews (TSX:GEN) has appointed Leslie Auld as CFO and treasurer, succeeding Sonny Young, who will continue to work with the company in a consulting capacity. Ms. Auld, who was retained by GeneNews as a financial consultant at the start of 2010, was most recently a consultant to Attwell Capital, formerly Fralex Therapeutics, and previously CFO [...]

Next Page »